Eli Lilly Is Near Its High. Bank of America Sees Another 19%

Bank of America raised its price target for Eli Lilly to $1,600, citing strong revenue growth and potential in new drugs. Lilly's Q3 revenue grew 39%, and it raised its 2026 guidance to $91B-$92B. The stock is up 25% in 2026 but remains 7% below its recent high. Bank of America's target is based on Lilly's growth profile and upcoming drug developments.

Original reporting
Published Nov 21, 2026, 2:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 21, 2026, 2:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Eli Lilly Is Near Its High. Bank of America Sees Another 19% — source image
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The target increase could attract new buying, but valuation remains high.

02

Market read

Analyst upgrade for a mega‑cap biotech may influence sector sentiment and short‑term price action.

03

What to watch

Potential regulatory or competitive risks from Novo Nordisk are not fully priced in.

Relevance 7/10Novelty 6/10Timing: today

Background

Eli Lilly reported strong Q3 revenue growth and raised its 2026 revenue guidance, prompting analyst target revisions.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Bank of America raised its price target for Eli Lilly to $1,600, a 19% increase, and kept a Buy rating, indicating fresh analyst optimism.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise is new information and aligns with strong revenue growth and guidance, prompting buying interest.

Market effects

Positive outlook may lift other pharma peers as growth expectations rise.

U.S. biotech sector could see modest gains.

Limited to investors tracking large-cap biotech stocks.

Counterpoint

Some may argue the target is overly optimistic given valuation levels.

Key entities

  • Eli Lilly (LLY)

    Pharmaceutical company receiving an upgraded price target.

  • Bank of America

    Equity research firm that raised the price target.

Related articles

$LLYMed

Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight

Eli Lilly's weight-loss drug, Zepbound, showed significant efficacy in a clinical trial for adolescents aged 12 to 17, with participants losing an average of 40 pounds. This could expand Zepbound's market to over 5 million U.S. patients, potentially adding $6.5 billion in annual revenue for Eli Lilly. The company's Q3 earnings showed strong growth, with Zepbound generating $5.4 billion in revenue.

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.